Suboptimal medication adherence may favor the progression of vertebral fractures in women with post-menopausal osteoporosis treated with denosumab-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Suboptimal medication adherence may favor the progression of vertebral fractures in women with post-menopausal osteoporosis treated with denosumab

Published:2020-09 Issue:3 Volume:45 Page:
ISSN:0391-1977
Container-title:Minerva Endocrinologica
language:
Short-container-title:Minerva Endocrinol

Author:

Betella Nazarena,Biamonte Emilia,Matarazzo Carmine,Piccini Sara,Olivetti Roberto,Cellini Miriam,Lania Andrea G.,Mazziotti Gherardo

Publisher

Edizioni Minerva Medica

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://www.minervamedica.it/pdf.php?cod=R07Y2020N03A0165

Reference39 articles.

1. A Model of Lifetime Osteoporosis Impact

2. New understanding and treatments for osteoporosis

3. Clinical Evaluation of Cost Efficacy of Drugs for Treatment of Osteoporosis: A Meta-Analysis

4. THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis

5. Fracture Incidence and Characterization in Patients on Osteoporosis Treatment: The ICARO Study

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bone-active drugs in premenopausal women with breast cancer under hormone-deprivation therapies;European Journal of Endocrinology;2024-07-26

2. Zoledronate After Denosumab Discontinuation: Is Repeated Administrations More Effective Than Single Infusion?;The Journal of Clinical Endocrinology & Metabolism;2024-04-13

3. Adherence of denosumab treatment for low bone mineral density in Japanese people living with HIV: a retrospective observational study;Journal of Pharmaceutical Health Care and Sciences;2023-12-07

4. Denosumab treatment lapses, discontinuation, and off-treatment fracture risk: A retrospective study of patients with osteoporosis in a real-world clinical setting;Bone;2023-12

5. Gestione clinica della terapia con Denosumab: in chi, quando e come interromperla;L'Endocrinologo;2023-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3